C4 Therapeutics, Inc. Logo

C4 Therapeutics, Inc.

Developing protein degrader medicines to treat cancer and other serious diseases.

CCCC | NDAQ

Overview

Corporate Details

ISIN(s):
US12529R1077
LEI:
Country:
United States of America
Address:
490 ARSENAL WAY, 2472 WATERTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on developing a new class of medicines through targeted protein degradation (TPD). The company's approach utilizes the body's natural protein disposal mechanisms to selectively eliminate disease-causing proteins. C4T leverages its proprietary TORPEDO® (Target Oriented Protein Degrader Optimizer) platform to design and advance a pipeline of small-molecule drug candidates aimed at treating cancer and other serious diseases. Its portfolio includes clinical programs such as Cemsidomide (CFT7455), CFT8919, and CFT1946.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all C4 Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for C4 Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for C4 Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea 471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea 068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America CERO

Talk to a Data Expert

Have a question? We'll get back to you promptly.